Boston Scientific Closes Symetis Acquisition

Medical Devices Directory Forums Business Partnering Boston Scientific Closes Symetis Acquisition

This topic contains 0 replies, has 1 voice, and was last updated by  Brückenkopf GmbH 10 months, 1 week ago.

Viewing 1 post (of 1 total)
  • Author
  • #4794

    Boston Scientific announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices.

    With the completion of the acquisition, Boston Scientific will immediately begin selling the ACURATE TA™ and ACURATE neo™/TF™ valve* systems in Europe and in other geographies outside of the United States, and Symetis will become part of the Boston Scientific Interventional Cardiology division.

    The two organizations announced a definitive agreement on March 30, 2017 for Boston Scientific to acquire the Symetis business for $435 million in cash.

Viewing 1 post (of 1 total)

You must be logged in to reply to this topic.